Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND Programmed cell death-1 (PD-1)/ programmed death-ligand 1 (PD-L1) blockade is currently widely used in the treatment of metastatic non-small cell lung cancer (NSCLC). Despite available biomarker stratification, clinical responses vary. Thus, the search for novel biomarkers with improved response prediction is ongoing. Previously, using mass cytometry deep immune-profiling (CyTOF), our group provided evidence that CD39+CD8+ T cells represent tumor antigen-specific, cytotoxic T cells in treatment-naïve NSCLC. We hypothesized that accurate quantitation of this T cell subset would predict immunotherapy outcome. METHODS In order to translate this to a clinical setting, the present study compared CyTOF data to results obtained via a range of clinically relevant methods; including conventional immunohistochemistry (IHC), multiplex immunohistochemistry/immunofluorescence (mIHC/IF), and gene expression assay by NanoString. RESULTS Quantification using mIHC/IF but not conventional IHC or NanoString correlated with the CyTOF results. The specificity and sensitivity of mIHC/IF was then assessed in a separate retrospective NSCLC cohort. CD39+CD8+ T cell proportion, as determined by mIHC/IF, successfully stratified responders and non-responders to PD-1/PD-L1 inhibitors (Objective Response Rate 63.6%, compared to 0% for the negative group). This predictive capability was independent from other confounding factors, such as total CD8+ T cell proportion, CD39+ lymphocyte proportion, PD-L1 positivity, epidermal growth factor receptor mutation status, and other clinicopathological parameters. CONCLUSION Our results suggest that the mIHC/IF platform is a clinically relevant method to assess CD39+CD8+ T cell proportion and this marker can serve as a potential biomarker that predicts response to PD-1/PD-L1 blockade in NSCLC patients. Further validation in additional NSCLC cohorts is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370
Self-citationDavis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938
Garnelo, M., Tan, A., Her, Z., Yeong, J., Lim, C. J., Chen, J., Lim, K. H., Weber, A., Chow, P., Chung, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310814 · Cited by 461
Self-citationFumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0220-9 · Cited by 176
Cited by
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 672
Vanguri, R. S., Luo, J., Aukerman, A. T., Egger, J. V., Fong, C. J., Horvat, N., Pagano, A., Araujo-Filho, J. D. A. B., Geneslaw, L., Rizvi, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00416-8 · Cited by 395
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Metadata
- Authors
- Yeong, J., Suteja, L., Simoni, Y., Lau, K. W., Tan, A. C., Li, H. H., Lim, S., Loh, J. H., Wee, F. Y. T., Nerurkar, S. N., Takano, A., Tan, E. H., Lim, T. K. H., Newell, E. W., & Tan, D. S. W.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 16
- Issue
- 8
- Pages
- 1349-1358
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3161640011
- Cited by
- 83
- References
- 8
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.